Compare Quest Diagnostics Inc (DGX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tidewater Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Tidewater Inc trades at $91.5 (market cap $4.54B). The key difference: Quest Diagnostics Inc is far larger — about 5.8× Tidewater Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| DGX | TDW | |
|---|---|---|
Market Cap | $26.21B | $4.54B |
Sector | Health | Utilities |
52-Week High | $238.50 | $91.20 |
52-Week Low | $173.49 | $47.29 |
Enterprise Value | $31.97B | $4.58B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Tidewater (TDW) trades at $91.86, up 2.49% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 earnings of $0.43 per share, beating estimates (Zacks, August 3, 2026), though it missed expectations in prior quarters. Revenue for the quarter was $342.3 million, with net income margins around 18%. Analyst sentiment is mixed, with 26.92% recommending Buy and 57.7% Hold.
Outlook: Strong day rates and utilization support revenue growth, but earnings misses and Middle East operational costs pose risks. The stock's valuation (P/E 18.5) is reasonable, but investors face volatility from oil market exposure and execution challenges. Upside depends on sustained operational improvements and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
